Abstract
Schwann cells are critically important for tissue repair, axonal regrowth and remyelination following injury to peripheral nerves. The absence of Schwann cells or an equivalent cell type in the central nervous system (CNS) may limit the regeneration capacity of the CNS. Mesenchymal stem cells (MSCs) have therefore been investigated for their potential to be induced to develop a Schwann cell phenotype. The methods for derivation of Schwann cell-like cells from MSCs and the benefits and limitations of each of these methods are presented in this review. Issues related to instability of the derived Schwann cell phenotype, apoptosis of derived cells in transplants, and the inability to predict with confidence how the cells will behave after transplantation are discussed. Finally, we suggest the need for further elucidation of the biology of Schwann cell differentiation and the signals for their derivation from MSC, in order to resolve these obstacles and to enable transplantation of MSC-derived Schwann cells as a therapeutic strategy in CNS injury.
Keywords: Mesenchymal stem cells, Schwann cells, spinal cord injury, two-step induction, stem cell co-culture, peripheral nervous system, central nervous system, embryonic stem cells, induced pluripotent stem cells, neural stem cels, olfactory ensheathing cells
CNS & Neurological Disorders - Drug Targets
Title: Derivation of Clinically Applicable Schwann Cells from Bone Marrow Stromal Cells for Neural Repair and Regeneration
Volume: 10 Issue: 4
Author(s): Sa Cai, Graham K.H. Shea, Alex Y.P. Tsui, Ying-Shing Chan and Daisy K.Y. Shum
Affiliation:
Keywords: Mesenchymal stem cells, Schwann cells, spinal cord injury, two-step induction, stem cell co-culture, peripheral nervous system, central nervous system, embryonic stem cells, induced pluripotent stem cells, neural stem cels, olfactory ensheathing cells
Abstract: Schwann cells are critically important for tissue repair, axonal regrowth and remyelination following injury to peripheral nerves. The absence of Schwann cells or an equivalent cell type in the central nervous system (CNS) may limit the regeneration capacity of the CNS. Mesenchymal stem cells (MSCs) have therefore been investigated for their potential to be induced to develop a Schwann cell phenotype. The methods for derivation of Schwann cell-like cells from MSCs and the benefits and limitations of each of these methods are presented in this review. Issues related to instability of the derived Schwann cell phenotype, apoptosis of derived cells in transplants, and the inability to predict with confidence how the cells will behave after transplantation are discussed. Finally, we suggest the need for further elucidation of the biology of Schwann cell differentiation and the signals for their derivation from MSC, in order to resolve these obstacles and to enable transplantation of MSC-derived Schwann cells as a therapeutic strategy in CNS injury.
Export Options
About this article
Cite this article as:
Cai Sa, K.H. Shea Graham, Y.P. Tsui Alex, Chan Ying-Shing and K.Y. Shum Daisy, Derivation of Clinically Applicable Schwann Cells from Bone Marrow Stromal Cells for Neural Repair and Regeneration, CNS & Neurological Disorders - Drug Targets 2011; 10 (4) . https://dx.doi.org/10.2174/187152711795563930
DOI https://dx.doi.org/10.2174/187152711795563930 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Role of Nuclear Factor Kappa B (NF-κB) Signalling in Neurodegenerative Diseases: An Mechanistic Approach
Current Neuropharmacology Non-Invasive Imaging of Human Embryonic Stem Cells
Current Pharmaceutical Biotechnology Variability in the Effects of Nicotine on Different Regions of the Brain: Changes in the Concentration of Superoxide Dismutase Isoforms
Central Nervous System Agents in Medicinal Chemistry Spinal Cord Ischemia/Injury
Current Pharmaceutical Design Novel Genetic and Peptide-Based Strategies Targeting the Bcl-2 Family, an Update
Recent Patents on DNA & Gene Sequences Research on the Possibility of Overcoming Traumatic Paraplegia and Its First Clinical Results
Current Pharmaceutical Design Guanylate Cyclase C: A Current Hot Target, from Physiology to Pathology
Current Medicinal Chemistry Imidazoline Receptors, Novel Agents and Therapeutic Potential
Cardiovascular & Hematological Agents in Medicinal Chemistry Eph Receptors as Drug Targets: Single-Chain Antibodies and Beyond
Current Drug Targets Treatment of Tachycardia in Hypertension: Where Do We Stand Now?
Current Hypertension Reviews The Axonal Transcriptome: RNA Localization and Function
Current Chemical Biology Oxidative Stress Modulation Through Habitual Physical Activity
Current Pharmaceutical Design Cannabinoids and Sensory Neurones
Current Neuropharmacology PPARγ: Potential Therapeutic Target for Ailments Beyond Diabetes and its Natural Agonism
Current Drug Targets Leptin as a Novel Therapeutic Target for Immune Intervention
Current Drug Targets - Inflammation & Allergy Measurement of Palmitoylethanolamide and Other N-Acylethanolamines During Physiological and Pathological Conditions
CNS & Neurological Disorders - Drug Targets The Response of the Aged Brain to Stroke: Too Much, Too Soon?
Current Neurovascular Research Patent Selections
Recent Patents on Inflammation & Allergy Drug Discovery Biphasic Mechanisms of Neurovascular Unit Injury and Protection in CNS Diseases
CNS & Neurological Disorders - Drug Targets Editorial (Hot Topic: Neuroprotection Against Stroke and CNS Injury: New Mechanisms, Targets, and Controversies)
CNS & Neurological Disorders - Drug Targets